ALZN · Company research
Alzamend Neuro, Inc. (ALZN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Alzamend Neuro (ALZN) Edges Lower to $1.34 as Shares Sit Near Lower Support - Institutional Sentiment - https://www.siam.in/ | Alzamend Neuro (ALZN) Edges Lower to $1.34 as Shares Sit Near Lower Support - Institutional Sentiment https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 14, 2026 | neutral | 0 | 0.6 |
| No shares sold: Alzamend Neuro (ALZN) requests withdrawal of a resale registration. - Stock Titan | No shares sold: Alzamend Neuro (ALZN) requests withdrawal of a resale registration. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? | Alzamend Neuro has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 59.6% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? | Alzamend Neuro has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 59.6% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? | Alzamend Neuro has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 59.6% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance | Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro (ALZN) Drops 19.77% to $1.39 as Microcap Biotech Selloff Deepens - Low Risk Entry Stocks - https://www.dars.gov.et/ | Alzamend Neuro (ALZN) Drops 19.77% to $1.39 as Microcap Biotech Selloff Deepens - Low Risk Entry Stocks https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 1, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro (ALZN) Drops 19.77% to $1.39 as Microcap Biotech Selloff Deepens - Dealer Positioning - www.dars.gov.et | Alzamend Neuro (ALZN) Drops 19.77% to $1.39 as Microcap Biotech Selloff Deepens - Dealer Positioning www.dars.gov.et | View source ↗ | www.dars.gov.et | Oct 1, 2026 | neutral | 0 | 0.6 |
| ALZN Q2 2026 Earnings: Wider-Than-Expected Loss for Pre-Revenue Biotech, Shares Still Edge Higher - Profit Recovery Report - dars.gov.et | ALZN Q2 2026 Earnings: Wider-Than-Expected Loss for Pre-Revenue Biotech, Shares Still Edge Higher - Profit Recovery Report dars.gov.et | View source ↗ | dars.gov.et | Sep 16, 2026 | neutral | 0 | 0.6 |
| Nasdaq closes listing matter after Alzamend shows $5.8 million in equity - Stock Titan | Nasdaq closes listing matter after Alzamend shows $5.8 million in equity Stock Titan | View source ↗ | Stock Titan | Sep 16, 2026 | neutral | 0 | 0.6 |
| Alzamend's first-of-its-kind lithium brain imaging data heads to Barcelona - Stock Titan | Alzamend's first-of-its-kind lithium brain imaging data heads to Barcelona Stock Titan | View source ↗ | Stock Titan | Aug 18, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key Support - Supply Zone - dars.gov.et | Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key Support - Supply Zone dars.gov.et | View source ↗ | dars.gov.et | Aug 6, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key Support - Buyback Factor - dars.gov.et | Alzamend Neuro (ALZN) Drops 3.5% to $1.38 as Shares Approach Key Support - Buyback Factor dars.gov.et | View source ↗ | dars.gov.et | Aug 6, 2026 | neutral | 0 | 0.6 |
| ALZN Forecast — Price Target — Prediction for 2027 - TradingView | ALZN Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Stocktwits | Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled Stocktwits | View source ↗ | Stocktwits | May 29, 2025 | neutral | 0 | 0.6 |
| Alzamend Neuro: ALZN Stock Price Quote & News - Robinhood | Alzamend Neuro: ALZN Stock Price Quote & News Robinhood | View source ↗ | Robinhood | Jul 22, 2023 | neutral | 0 | 0.6 |
| What is the current Price Target and Forecast for Alzamend Neuro (ALZN) - Zacks Investment Research | What is the current Price Target and Forecast for Alzamend Neuro (ALZN) Zacks Investment Research | View source ↗ | Zacks Investment Research | May 10, 2023 | neutral | 0 | 0.6 |
| 6 Penny Stocks With 1,000% Upside Potential - InvestorPlace | 6 Penny Stocks With 1,000% Upside Potential InvestorPlace | View source ↗ | InvestorPlace | Jul 24, 2022 | neutral | 0 | 0.6 |
| Alzamend Neuro, Inc. (ALZN) stock price, news, quote and history - Yahoo Finance Australia | Alzamend Neuro, Inc. (ALZN) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Aug 16, 2021 | neutral | 0 | 0.6 |
| Alzamend Neuro, Inc. (ALZN) Stock Price, News, Quote & History - Yahoo! Finance Canada | Alzamend Neuro, Inc. (ALZN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Jun 23, 2021 | neutral | 0 | 0.6 |
| ALZN Stock Price and Chart — NASDAQ:ALZN - TradingView | ALZN Stock Price and Chart — NASDAQ:ALZN TradingView | View source ↗ | TradingView | Jun 15, 2021 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.